Skip to content

Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect

Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect (ATAX)

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03769961
Acronym
ATAX
Enrollment
6
Registered
2018-12-10
Start date
2018-12-01
Completion date
2020-09-14
Last updated
2020-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ataxia, Cerebellar Diseases, Deep Brain Stimulation, Essential Tremor

Keywords

essential tremor, dbs

Brief summary

The proposed study aims to characterize ataxia occurring in essential tremor and essential tremor with DBS.

Detailed description

Objectives: In recent years, there has been a growing amount of evidence tying Essential Tremor (ET) to cerebellar dysfunction. This has been clinically observed, demonstrated through specific gait measures of ataxia (often involving tandem gait), and confirmed through Positron emission tomography (PET) imaging. Deep Brain stimulation for ET has become a widely utilized therapeutic intervention for patients, and the bilateral thalamic ventralis intermedius (VIM) is most commonly implanted. However, it has been noted that in some patients gait ataxia significantly worsens post-op. This initially was thought to be a result of disease progression, but recent studies have in fact shown that this is a DBS related phenomenon. Methods: Participants will have two visits to either the Portland VA or Oregon Health & Science University (OHSU). At each visit, several assessments of balance, tremor, gait and balance, and DBS settings will be made. The gait and balance assessments will be performed by a unblinded and a blinded rater.

Interventions

OTHERNo intervention

No interventions - Observational study

Sponsors

Portland VA Medical Center
CollaboratorFED
Oregon Health and Science University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Essential Tremor diagnosis at least 3 years duration * Absence of other neurological signes (such as dystonia, ataxia, or Parkinsonism) * Patients must be able to walk 2 minutes unassisted. * Patients must be able to understand and consent to be in the study.

Exclusion criteria

* Patients who have had changes in DBS settings within the last 3 months. * Patients who have had no initial improvement or response to DBS. * ET medication changes in the last month. * Actively abusing alcohol. * A neurologic diagnosis other than ET that in the investigator's opinion could affect gait and/or balance. * Atypical tremor disorder including by not limited to tremor due to multiple sclerosis, medication-induced tremor, Parkinson's disease, or parkinsonian syndrome. * Dementia

Design outcomes

Primary

MeasureTime frameDescription
Ataxia Differences between DBS and no DBSVisit 2 (after DBS has been turned off for 3-10 days)Compare the Scale of the Assessment and Rating of Ataxia (SARA) total score between DBS and no DBS participants with essential tremor. This 8-item scale rates gait (0-8 points), stance (0-6 points), sitting (0-4 points), speech disturbance (0-6 points), finger chase (0-4 points), nose-finger test (0-4 points), fast alternating hand movements (0-4 points), and heel-shin slide (0-4 points). Motor activists of the four extremities (items 5-8) assessments are performed bilaterally, mean values to obtain a total score. Cumulative score ranges from 0 (no ataxia) to 40 (most severe ataxia).

Secondary

MeasureTime frameDescription
Balance ConfidenceVisit 2 (after DBS has been turned off for 3-10 days)The Activities-Specific Balance Confidence Scale (ABC) is a subjective measure of confidence in performing various ambulatory activities without falling or experiencing a sense of unsteadiness. The ABC scale is a 16-item self-report measure in which participants rate their balance confidence on a 0-100 scale (0 = 0 no confidence, 100 = 100 complete confidence). Overall score is calculated by adding item scores and dividing by the total number of items.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026